Faeth Therapeutics stock, Roche collaboration

Faeth Therapeutics stock as Roche joins PIKTOR breast cancer trial

Published on 11/19/2026 at 02:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Faeth Therapeutics stock is in focus as the company enters a Roche collaboration. Faeth will retain PIKTOR rights while Roche supplies the study drug.

Roche collaboration expands PIKTOR path

  • Faeth will sponsor a Phase 1b/2 study of PIKTOR with Roche's investigational medicine giredestrant in advanced HR+/HER2-negative breast cancer.
  • Faeth retains all rights to PIKTOR while Roche supplies giredestrant for the trial.
  • Interim data from the breast cancer study is anticipated in 2027.
Faeth Therapeutics stock, Roche collaboration, PIKTOR, breast cancer, clinical-stage biotechnology, Illustration mit AI erstellt.

Faeth Therapeutics announced on November 16, 2026, that it had entered a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. The company release says the partnership will evaluate PIKTOR with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Roche supplies the combination partner

Faeth will sponsor and conduct the Phase 1b/2 FTH-PIK-101 study. Roche will supply giredestrant for use in the trial, while Faeth retains all rights to PIKTOR.

PIKTOR is an investigational all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. The first patient in the breast cancer study was dosed in April 2026, and interim data is anticipated in 2027.

Clinical-stage oncology focus

Faeth Therapeutics is a U.S.-based clinical-stage biotechnology company focused on multi-node inhibition of oncogenic pathways. Its lead program PIKTOR is being developed for endometrial and breast cancer, with an all-oral treatment approach. The company remains an early-development specialist rather than a commercial pharmaceutical business, with its value tied to clinical progress and future study results.

Faeth Therapeutics at a glance

  • Company: Faeth Therapeutics, Inc.
  • Ticker: FTH
  • Exchange: Nasdaq
  • Business: Clinical-stage oncology biotechnology
  • Lead program: PIKTOR

The broader U.S. market environment remains relevant for investors following the S&P 500.

Disclaimer...
en | boerse | 70533287 |